Introduction by Dr Peter RoseEditor, Thrombus
I am pleased to introduce www.CAThrombosis.com, an exclusive educational resource for UK and Ireland-based healthcare professionals working in the field of cancer-associated thrombosis (CAT).
CAT accounts for approximately 20% of venous thromboembolism (VTE) cases and is a leading cause of morbidity and mortality among cancer patients. In comparison to those without cancer, cancer patients are more likely to develop VTE events, making CAT a concern in both the oncology and haematology fields.1
Recently launched by LEO Pharma, www.CAThrombosis.com provides healthcare professionals with a variety of interactive and downloadable resources, including fully referenced and in-depth CAT-related articles, e-learning, videos and webinars, and an events calendar. The site also includes a CAT-customised content feed from PubMed.
Following registration, users are able to set email reminders for upcoming CAT-related events of interest, in addition to conveniently tracking and managing articles, research papers and educational modules within a secure environment.
All content has been independently sourced and developed in collaboration with key opinion leaders in CAT. LEO Pharma is committed to enhancing and updating the content of this site by adding new resources such as webinars, conference reports and interactive videos.
With rapid advances in the treatment and management of many cancers, it is easy to ignore or overlook the morbidity and mortality of cancer-associated thrombosis (CAT). It is, therefore, important to raise awareness of the second most common cause of death in patients with malignancy.
For those working primarily in the area of thrombosis, it is important to distinguish CAT from non-cancer associated venous thromboembolic disease (VTE). CAT has different factors in its pathogenesis and aetiology, different predisposing factors, requires a different pathway of investigation, different treatment and has a very different and poor prognosis.
To date, these differences have been largely ignored, with CAT often being investigated and treated along the same lines as non-cancer associated VTE. It must be remembered that nearly all cancer patients will have an abnormal VTE screening with the Well's score/raised D-dimer at presentation with suspected VTE, making these tests an unnecessary and unhelpful step in the investigation of VTE in cancer patients.
Increased CAT awareness
There is, therefore, a need for more initiatives that increase awareness of CAT, and the launch of www.CAThrombosis.com is to be welcomed. The site has been developed to provide a free educational resource for healthcare professionals, which is easy to access and regularly updated. This is a helpful resource for those wishing to become more familiar with the subject, with structured e-learning modules making it an excellent starting point. For those with a more in-depth knowledge, the site is regularly updated with the latest research articles and additional resources such as highlights, videos and webinars from important meetings. I would therefore encourage colleagues to visit www.CAThrombosis.com and incorporate the modules into oncology training programmes.
There is still a long way to go in terms of education and patient management in CAT, but it is hoped that greater awareness will ultimately have an impact on clinical outcomes.
- Connolly GC, Francis CW. Cancer-associated thrombosis. Hematology Am Soc Hematol Educ Program 2013; 2013: 684-691.
Dr Peter Rose has received an honorarium from LEO Pharma for the content development of this communication.